PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
Open accessThe DOI matches its Crossref record; 61 of the 63 references it cites were found in a registry or an index.
Abstract
Background and objectives: Progesterone is essential to maintain a healthy pregnancy. Guidance from the Royal College of Obstetricians and Gynaecologists and a Cochrane review called for a definitive trial to test whether or not progesterone therapy in the first trimester could reduce the risk of miscarriage in women with a history of unexplained recurrent miscarriage (RM). The PROMISE trial was conducted to answer this question. A concurrent cost-effectiveness analysis was conducted. Design and setting: A randomised, double-blind, placebo-controlled, international multicentre study, with economic evaluation, conducted in hospital settings across the UK (36 sites) and in the Netherlands (nine sites). Participants and interventions: Women with unexplained RM (three or more first-trimester losses), aged between 18 and 39 years at randomisation, conceiving naturally and giving informed consent, received either micronised progesterone (Utrogestan®, Besins Healthcare) at a dose of 400 mg (two vaginal capsules of 200 mg) or placebo vaginal capsules twice daily, administered vaginally from soon after a positive urinary pregnancy test (and no later than 6 weeks of gestation) until 12 completed weeks of gestation (or earlier if the pregnancy ended before 12 weeks). Main outcome measures: Live birth beyond 24 completed weeks of gestation (primary outcome), clinical pregnancy at 6–8 weeks, ongoing pregnancy at 12 weeks, miscarriage, gestation at delivery, neonatal survival at 28 days of life, congenital abnormalities and resource use. Methods: Participants were randomised after confirmation of pregnancy. Randomisation was performed online via a secure internet facility. Data were collected on four occasions of outcome assessment after randomisation, up to 28 days after birth. Results: A total of 1568 participants were screened for eligibility. Of the 836 women randomised between 2010 and 2013, 404 received progesterone and 432 received placebo. The baseline data (age, body mass index, maternal ethnicity, smoking status and parity) of the participants were comparable in the two arms of the trial. The follow-up rate to primary outcome was 826 out of 836 (98.8%). The live birth rate in the progesterone group was 65.8% (262/398) and in the placebo group it was 63.3% (271/428), giving a relative risk of 1.04 (95% confidence interval 0.94 to 1.15;p = 0.45). There was no evidence of a significant difference between the groups for any of the secondary outcomes. Economic analysis suggested a favourable incremental cost-effectiveness ratio for decision-making but wide confidence intervals indicated a high level of uncertainty in the health benefits. Additional sensitivity analysis suggested the probability that progesterone would fall within the National Institute for Health and Care Excellence’s threshold of £20,000–30,000 per quality-adjusted life-year as between 0.7145 and 0.7341. Conclusions: There is no evidence that first-trimester progesterone therapy improves outcomes in women with a history of unexplained RM. Limitations: This study did not explore the effect of treatment with other progesterone preparations or treatment during the luteal phase of the menstrual cycle. Future work: Future research could explore the efficacy of progesterone supplementation administered during the luteal phase of the menstrual cycle in women attempting natural conception despite a history of RM. Trial registration: Current Controlled Trials ISRCTN92644181; EudraCT 2009-011208-42; Research Ethics Committee 09/H1208/44. Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 41. See the NIHR Journals Library website for further project information.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant differences were observed in the former trial but not in the latter trial.”
From Recurrent MiscarriageGreen‐top Guideline No. 17 (2023) · cites this paper as [201]
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
An Efficient Method of Estimating Seemingly Unrelated Regressions and Tests for Aggregation Bias
Zellner, A. (1962) · Journal of the American Statistical Association · doi:10.1080/01621459.1962.10480664 · Cited by 8,401
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634 · cited 1×
“l A guideline by the RCOG and a Cochrane review called for a definitive trial to evaluate this research question.(12) l Participants in two unpublished surveys [one of women with RM (n= 88) and the other of gynaecologists (n= 102) treating women with RM] demonstrated an interest in progesterone therapy and a willingne…”
MethodA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008
(2011) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2010.02847.x · Cited by 2,994
Wood, L., Egger, M., Gluud, L. L., Schulz, K. F., Jüni, P., Altman, D. G., Gluud, C., Martin, R. M., Wood, A. J. G., & Sterne, J. A. C. (2008) · BMJ · doi:10.1136/bmj.39465.451748.ad · Cited by 2,538 · cited 1×
“One example of weak methodology was in lack of concealment, which has been shown to exaggerate effect sizes by up to 41%,(12) although there is some evidence that this exaggeration may not be a concern when the outcome is objective.(13) Small sample sizes increase the likelihood of random error (generating the wide CI…”
Equipoise and the Ethics of Clinical Research
Freedman, B. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707163170304 · Cited by 2,339
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Prevention of recurrent preterm delivery by 17 alpha–hydroxyprogesterone caproate
Meis, P. J., Klebanoff, M., Thom, E., Dombrowski, M. P., Sibai, B., Moawad, A. H., Spong, C. Y., Hauth, J. C., Miodovnik, M., Varner, M. W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035140 · Cited by 1,555
Research works printed but not linked: 25
- Regan, 2003, The Investigation and Treatment of Couples with Recurrent Miscarriage
- d-maps.com, United Kingdom/United Kingdom of Great Britain and Northern Ireland: Outlines, Nations, Color (White)
- d-maps.com, Netherlands/Koninkrijk der Nederlanden: Outline, Provinces, Color (White)
- US Food and Drug Administration Advisory Committee for Reproductive Health Drugs, 2003, Briefing Information for the September 29, 2003 Meeting of the Advisory Committee for Reproductive Health Drugs
- European Commission, 2003, Commission Directive 2003/94/EC of 8 October 2003
- European Commission, 2001, Commission Directive 2001/20/EC of 4 April 2001
- EudraLex, 2010, The Rules Governing Medicinal Products in the European Union, Volume 4: Guidelines for Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use – Annex 13, Manufacture of Investigational Medicinal Products
- Datapharm, Utrogestan Vaginal 200 mg Capsules – Summary of Product Characteristics
- Joint Formulary Committee, 2014, British National Formulary
- Great Britain, 2006, The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006
- Royal Pharmaceutical Society of Great Britain, 2005, The Safe and Secure Handling of Medicines: A Team Approach
- National Pharmacy Clinical Trials Advisory Group, 2013, Professional Guidance on Pharmacy Services for Clinical Trials, Version 1
- Imperial College London/Imperial College Healthcare NHS Trust Joint Research Compliance Office, 2015, Recording Managing and Reporting Adverse Events in the UK Imperial College of Science Technology and Medicine, Version 7.0
- Medical Research Council/Department of Health, Clinical Trials Toolkit 2007. Work Stream 6: Pharmacovigilance (Updated 2012)
- European Commission, 2006, Detailed Guidance on the Collection, Verification and Presentation of Adverse Reaction Reports arising from Clinical Trials on Medicinal Products for Human Use: Revision 2
- Great Britain, 1998, Data Protection Act 1998
- Department of Health, 2003, Confidentiality: NHS Code of Practice
- Department of Health, The Caldicott Committee, 1997, Report on the Review of Patient-Identifiable Information
- Department of Health, 2005, Research Governance Framework for Health and Social Care, Second Edition
- Involve, 2009, Public Involvement in the Management for the Research Design Service
- Gardosi, 2013, Customised Weight Centile Calculator
- Department of Health, 2012, Reference Costs 2011–12
- National Collaborating Centre for Women’s and Children’s Health, 2012, Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management in Early Pregnancy of Ectopic Pregnancy and Miscarriage
- Maternal Critical Care Working Group, 2011, Providing Equity of Critical and Maternity Care for the Critically Ill Pregnant or Recently Pregnant Woman
- National Institute for Health and Care Excellence, 2013, Guide to the Methods of Technology Appraisal 2013
Cited by
Quenby, S., Gallos, I. D., Dhillon-Smith, R. K., Podesek, M., Stephenson, M. D., Fisher, J., Brosens, J. J., Brewin, J., Ramhorst, R., Lucas, E. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00682-6 · Cited by 1,560
Self-citationDodd, J. M., Jones, L., Flenady, V., Cincotta, R., & Crowther, C. A. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004947.pub3 · Cited by 331
Progesterone-Related Immune Modulation of Pregnancy and Labor
Shah, N. M., Lai, P. F., Imami, N., & Johnson, M. R. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00198 · Cited by 217
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Vuitton, L., Moreau, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313060 · Cited by 160
Steroid hormones and pregnancy
Noyola-Martínez, N., Halhali, A., & Barrera, D. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1564742 · Cited by 158
“Regarding the prevention of miscarriages, the results of a randomized, double-blind, placebo-controlled and international multicenter study have demonstrated that vaginal micronized P4 administration in early pregnancy did not result in significant decrease in unexplained recurrent miscarriages as compared with placeb…”
ResultRecurrent MiscarriageGreen‐top Guideline No. 17
Regan, L., Rai, R., Saravelos, S., Li, T., & the Royal College of Obstetricians and Gynaecologists (2023) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17515 · Cited by 158
Self-citationZaat, T. R., Kostova, E. B., Korsen, P., Showell, M. G., Mol, F., & van Wely, M. (2023) · Human Reproduction Update · doi:10.1093/humupd/dmad011 · Cited by 133
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Hathaway, T. J., & Ramsey, P. S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub4 · Cited by 130
Progesterone: A Unique Hormone with Immunomodulatory Roles in Pregnancy
Raghupathy, R., & Szekeres‐Barthó, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031333 · Cited by 121
“A randomized doubleblind, placebo-controlled study on women with unexplained recurrent miscarriage who received micronized progesterone in the first trimester found no evidence for improved live-birth rates as compared to women who received a placebo [97].”
BackgroundRespiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment
Gu, X., Zhou, F., Wang, Y., Fan, G., & Cao, B. (2020) · European Respiratory Review · doi:10.1183/16000617.0038-2020 · Cited by 136
Progestogens for preventing miscarriage: a network meta-analysis
Devall, A., Papadopoulou, A., Podesek, M., Haas, D. M., Price, M. J., Coomarasamy, A., & Gallos, I. D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013792.pub2 · Cited by 144
Self-citationReview article: dose optimisation of infliximab for acute severe ulcerative colitis
Hindryckx, P., Novak, G., Casteele, N. V., Laukens, D., Parker, C. E., Shackelton, L. M., Narula, N., Khanna, R., Dulai, P. S., Levesque, B. G., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13913 · Cited by 95
Surgery in the age of biologics
Wong, D. J., Roth, E. M., Feuerstein, J. D., & Poylin, V. Y. (2019) · Gastroenterology report · doi:10.1093/gastro/goz004 · Cited by 90
Dodd, J. M., Grivell, R. M., O’Brien, C. M., Dowswell, T., & Deussen, A. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012024.pub2 · Cited by 86
Schuetz, P., Sulo, S., Walzer, S., Vollmer, L., Brunton, C., Kaegi-Braun, N., Stanga, Z., Mueller, B., & Gomes, F. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046402 · Cited by 67
Ordás, Í., Domènech, E., Mañosa, M., García-Sánchez, V., Iglesias-Flores, E. M., Peñalva, M., Cañas-Ventura, A., Merino, O., Fernández‐Bañares, F., Gomollón, F., et al. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.180 · Cited by 66
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Hathaway, T. J., & Ramsey, P. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub5 · Cited by 75
The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility
Czyzyk, A., Podfigurna, A., Genazzani, A. R., & Męczekalski, B. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1291615 · Cited by 63
“Due to limitations of previous studies, a PROMISE international multicentre trial has been conducted, which addressed the role of progesterone supplementation (400 mg vaginally from positive pregnancy test to 12th week of gestation) in women with recurrent miscarriage (n1⁄4 836) [29].”
MethodHennelly, N., Cooney, A., Houghton, C., & O’Shea, E. (2021) · The Gerontologist · doi:10.1093/geront/gnz159 · Cited by 61
Lappas, B. M., Patel, D. A., Kumpf, V. J., Adams, D. W., & Seidner, D. L. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.10.001 · Cited by 72
Beswick, L., Rosella, O., Rosella, G., Headon, B., Sparrow, M., Gibson, P. R., & van Langenberg, D. R. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx146 · Cited by 52
Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT
Coomarasamy, A., Harb, H. M., Devall, A., Cheed, V., Roberts, T. E., Goranitis, I., Ogwulu, C. B., Williams, H., Gallos, I. D., Eapen, A. K., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24330 · Cited by 57
Self-citationBoyers, D., Retat, L., Jacobsen, E., Avenell, A., Aveyard, P. N., Corbould, E., Jaccard, A., Cooper, D., Robertson, C., Aceves‐Martins, M., et al. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00849-8 · Cited by 55
Immunomodulation for unexplained recurrent implantation failure: where are we now?
Genest, G., Banjar, S., Almasri, W., Beauchamp, C., Benoit, J., Buckett, W. M., Dzineku, F., Gold, P., Dahan, M. H., Jamal, W., et al. (2022) · Reproduction · doi:10.1530/rep-22-0150 · Cited by 51
Implications of telomeres and telomerase in endometrial pathology
Hapangama, D. K., Kamal, A. M., & Saretzki, G. C. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw044 · Cited by 52
“Progesterone is commonly employed to treat women with a variety of reproductive failures, from infertility, to luteal phase defects to recurrent miscarriages, yet the available evidence on the effectiveness of this therapy is inconclusive (Coomarasamy et al., 2016).”
BackgroundMümüşoğlu, S., Telek, S. B., & Ata, B. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.08.326 · Cited by 47
Thomas, M. G., Bayliss, C., Bond, S. J., Dowling, F., Galea, J. P., Jairath, V., Lamb, C. A., Probert, C. S., Timperley-Preece, E., Watson, A. J. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-023765 · Cited by 43
Supplemental parenteral nutrition in intensive care patients: A cost saving strategy
Pradelli, L., Graf, S., Pichard, C., & Berger, M. M. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.009 · Cited by 42
Clement, C., Edwards, S., Rapport, F., Russell, I. T., & Hutchings, H. A. (2018) · Trials · doi:10.1186/s13063-018-2983-y · Cited by 46
Investigation and Management of Recurrent Pregnancy Loss: A Comprehensive Review of Guidelines
Giouleka, S., Tsakiridis, I. G., Arsenaki, E., Kalogiannidis, I. A., Mamopoulos, A. M., Papanikolaou, E. G. E., Athanasiadis, A. P., & Dagklis, T. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001133 · Cited by 41
Colectomy rates for ulcerative colitis in England 2003‐2016
Worley, G., Almoudaris, A. M., Bassett, P., Segal, J. P., Akbar, A., Ghosh, S. K., Aylin, P. P., & Faiz, O. D. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16202 · Cited by 39
Efficacy of progesterone on threatened miscarriage: Difference in drug types
Wang, X., Luo, Q., & Bai, W. (2019) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13909 · Cited by 36
Katalinic, A., SHULMAN, L. P., Strauss, J. F., García-Velasco, J. A., & van den Anker, J. N. (2022) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2022.03.032 · Cited by 45
Sheng, Y., Hou, S., Hu, W., Wei, C., Liu, Y., Liu, Y.-Y., Jiang, L., Xiang, J., Sun, X., Lei, C., et al. (2021) · Genes · doi:10.3390/genes12020141 · Cited by 34
“Obstetricians and Gynecologists (RCOG) as at least three consecutive miscarriages before 24 weeks of gestation [3].”
BackgroundWang, S., Li, M., Sun, F., Chen, C., Ye, J., Li, D., Qian, J., & Du, M. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9469 · Cited by 30
“As co‐stimulatory signals have important roles in T‐cell function and pregnancy maintenance (18,28), despite the lack of evidence regarding improved outcomes following first‐trimester progesterone therapy in females with a history of RSA (40,41), the results of the present study suggested that P4 may also have an immu…”
BackgroundLower frequency of the HLA-G UTR-4 haplotype in women with unexplained recurrent miscarriage
Meuleman, T., Drabbels, J. J. M., Lith, J. M. M. V., Dekkers, O. M., Rozemuller, E. H., Cretu-Stancu, M., Claas, F. H. J., Bloemenkamp, K. W. M., & Eikmans, M. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.02.002 · Cited by 28
Self-citationWatters, M., Noble, M., Child, T. J., & Nelson, S. M. (2019) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2019.10.009 · Cited by 28
Gumber, L., Agbeleye, O., Inskip, A., Fairbairn, R., Still, M., Ouma, L. O., Lozano-Kühne, J., Bardgett, M., Isaacs, J. D., Wason, J. M. S., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-077132 · Cited by 32
Female reproductive health and inflammatory bowel disease: A practice-based review
Armuzzi, A., Bortoli, A., Castiglione, F., Contaldo, A., Daperno, M., Renata D'Incà, Labarile, N., Mazzuoli, S., Onali, S., Milla, M., et al. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.05.020 · Cited by 36
Paternal HLA ‐C is a risk factor in unexplained recurrent miscarriage
Meuleman, T., Haasnoot, G. W., Lith, J. M. M. V., Verduijn, W., Bloemenkamp, K. W. M., & Claas, F. H. J. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12797 · Cited by 31
Self-citationManning, R., Iyer, J., Bulmer, J. N., Maheshwari, A., & Choudhary, M. K. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1803241 · Cited by 26
“Although a subgroup analysis of small studies showed reduced miscarriage incidence with progesterone therapy (Haas and Ramsey, 2008), the large PROMISE RCT demonstrated no benefit (Coomarasamy et al. 2016).”
BackgroundResultInfluentialDiagnostic Evaluation of Chronic Pelvic Pain
Khatri, G., Khan, A., Raval, G., & Chhabra, A. B. (2017) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/j.pmr.2017.03.004 · Cited by 22
Rapport, F., Clement, C., Seagrove, A. C., Alrubaiy, L., Hutchings, H. A., & Williams, J. G. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1085-y · Cited by 26
The Role Of Progestogens In Threatened And Idiopathic Recurrent Miscarriage
Arab, H., Alharbi, A. J., Oraif, A., Sagr, E. R., Madani, H. A., Abduljabbar, H. S., Bajouh, O. S., Faden, Y. A., & Sabr, Y. (2019) · International Journal of Women s Health · doi:10.2147/ijwh.s224159 · Cited by 33
“The multicenter, randomized, double-blind, placebocontrolled PROMISE study exploring the effect of micronized vaginal progesterone (400 mg capsules) in women with a history of unexplained recurrent miscarriage (n = 836; 404 progesterone, 432 placebo) did not find any benefit of vaginal progesterone in improving rates…”
ResultQian, Y., Walters, S. J., Jacques, R., & Flight, L. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051673 · Cited by 27
Laharie, D., Bourreille, A., Branche, J., Allez, M., Bouhnik, Y., Filippi, J., Zerbib, F., Savoye, G., Vuitton, L., Moreau, J., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.001 · Cited by 22
Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis
Walsh, A. J., Matini, L., Hinds, C., Sexton, V., Brain, O., Keshav, S., Geddes, J. R., Goodwin, G. M., Collins, P. G. S., Travis, S. P. L., et al. (2019) · Intestinal Research · doi:10.5217/ir.2018.00173 · Cited by 20
The role of uterine natural killer cells in recurrent pregnancy loss and possible treatment options
Béquet, Y. L. B. N., Lashley, E. E. L. O., Goddijn, M., & van der Hoorn, M. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.08.949 · Cited by 20
Self-citationSzemes, K., Soós, A., Hegyi, P. J., Farkas, N., Erös, A., Erőss, B. M., Mezősi, E., Szakács, Z., Márta, K., & Sarlós, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2019.00338 · Cited by 20
Guideline No. 464: Recurrent Pregnancy Loss
Motan, T., Cockwell, H., Elliott, J., Antaki, R., & White, J. S. (2025) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2025.103167 · Cited by 19
Management of recurrent miscarriages: an overview of current evidence
Tsonis, O., Balogun, S., Adjei, J. O., Mogekwu, O., & Iliodromiti, S. (2021) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000735 · Cited by 18
Zhou, H., Yang, Y., Deng, L., Yao, Y., & Liao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775245 · Cited by 18
Devall, A., Chu, J., Beeson, L. E., Hardy, P., Cheed, V., Sun, Y., Roberts, T. E., Ogwulu, C. B., Williams, E. V., Jones, L. L., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25680 · Cited by 13
Self-citationRelph, S. A., Delaney, L., Melaugh, A., Vieira, M. C., Sandall, J., Khalil, A. A., Pasupathy, D., & Healey, A. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040022 · Cited by 12
Touray, M. (2018) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12218 · Cited by 11
Luteal Phase Defects and Progesterone Supplementation
Collins, L. C., Gatta, L. A., Dotters-Katz, S. K., Kuller, J. A., & Schust, D. J. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001242 · Cited by 11
“48 It is also important to note that both trials highlighted the favorable safety profile associated with progesterone supplementation as neither reported any adverse effects, including increased rates of preeclampsia or small-for-gestational-age infants.”
Epidemiological trends in abortion and miscarriage between 1990 and 2019
Wang, Y., Tang, Y., Wang, G. ‐., Wei, R., Liu, L., & Lü, C. (2025) · Reproductive Health · doi:10.1186/s12978-025-02049-3 · Cited by 13
Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology
Haas, D. M., Rodriguez, M. B., Hathaway, T. J., & Ramsey, P. S. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003511.pub6 · Cited by 10
Rahnama, R., Rafiee, M., Fouladi, S., Akbari‐Fakhrabadi, M., Mehrabian, F., & Rezaei, A. (2019) · BMC Research Notes · doi:10.1186/s13104-019-4787-x · Cited by 8
Liu, X., Li, W., Mol, B. W., Wen, W., Wang, T., Tian, L., Li, N., Sun, T., Wang, T., Zhou, H., et al. (2023) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2023.10.012 · Cited by 8
Self-citationThe year in cardiology 2016: peripheral circulation
Carlo, M. D., Mazzolai, L., Bossone, E., Brodmann, M., Micari, A., Muiesan, M. L., Ricco, J., Stabile, E., Agnelli, G., Aboyans, V., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw643 · Cited by 7
Bernstein, C. N., & Kornbluth, A. A. (2017) · The American Journal of Gastroenterology · doi:10.1038/ajg.2017.282 · Cited by 7
Räuber, S. J., Pawlitzki, M., Korsen, M., Kullmann, J. S., Thoene, D., Pfeuffer, S., Rolfes, L., Nelke, C., Melzer, N., Ruck, T., et al. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103670 · Cited by 7
“As observational studies assessing adverse events (AEs; untoward medical occurrence in a patient irrespective of the causal relationship (Coomarasamy et al., 2016)), and adverse drug reactions (ADRs; injuries as a result of medication use (Bates et al., 1995)) are crucial to an adequate drug safety…”
BackgroundPregnancy outcomes following recurrent miscarriage
Fee, N., McEvoy, A., Cullen, S., Doyle, S., Crosby, D. A., & Allen, C. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03305-w · Cited by 11
Can we improve the outcome of pregnancies with low serum PAPP-A in the first trimester?
Tsibizova, V. I., Alsannan, B., Fedorova, A., Govorov, I., Meyyazhagan, A., & Renzo, G. C. D. (2024) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2024.2326303 · Cited by 5
“Two high-quality RCT studies, the PROMISE trial [23] and the PRISM trial [24], have shown that treatment with vaginal micronized progesterone (400 mg twice daily) was associated with increasing live birth rates according to the number of previous miscarriages.”
Mu, F., Huo, H., Wang, M., Liu, L., & Wang, F. (2024) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2024.104322 · Cited by 5
DANIELS, J. P., Dixon, E. F., Gill, A., Bishop, J., D’Amico, M., Ahmed, K., Dodds, J. P., Tryposkiadis, K., Wilks, M., Millar, M., et al. (2022) · Health Technology Assessment · doi:10.3310/bicf1187 · Cited by 10
Shargorodska, E. B., & Melenchuk, L. M. (2022) · Актуальні проблеми сучасної медицини Вісник Української медичної стоматологічної академії · doi:10.31718/2077-1096.22.2.116 · Cited by 14
Khanjani, S., Goodarzi, S., Khaleghi, M. M., Moosavi, S. S., Eshraghi, R., Meigoli, M. S. S., Fathi, M., Azadani, M. N., Sadraei, N., & Bahrami, A. (2025) · European journal of medical research · doi:10.1186/s40001-025-03382-w · Cited by 3
Progestogens and Recurrent Miscarriage
Katakam, N., & Nardo, L. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-52508-8_5 · Cited by 3
Xie, R., Wu, J., Shang, B., Bi, X., Cao, C., Guan, Y. F., Shi, H., & Shou, J. (2022) · Cancer Innovation · doi:10.1002/cai2.34 · Cited by 2
“Any noted unintentional or unfavorable clinical signs or symptoms, including complications of miscarriage in all ‐ causes were denoted as AEs [12].”
BackgroundGomaa, I. A., Sabry, A., Allam, I. S., Ashoush, S. A., & Reda, A. M. (2023) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0043-1776030 · Cited by 7
Góes, L. G., Vilariño, F. L., Oba, E., & Bondan, E. F. (2021) · Clínica e Investigación en Ginecología y Obstetricia · doi:10.1016/j.gine.2021.100724 · Cited by 2
Luteal phase deficiency: pathophysiology and role in reproductive disorders
Ivanov, I. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-3-89-97 · Cited by 3
Obstetric Indications for Progestin Therapy
Boelig, R. C. (2023) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2022.10.004 · Cited by 2
The Genetic and Genomic Landscape of Human Reproductive Disorders: An Overview with Our Experience
Halder, A., Sharma, P., Rana, R., Kalsi, A. S., Jain, M., & Sharma, M. (2023) · Medical Research Archives · doi:10.18103/mra.v11i3.3731 · Cited by 2
Khosravi, M., Rezapour, A., Moradi, N., Nassiri, S., & Azadi, N. (2024) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.38.54 · Cited by 1
Luteal Phase Defects and Progesterone Supplementation
Collins, L. C., Gatta, L. A., Dotters-Katz, S. K., Kuller, J. A., & Schust, D. J. (2024) · Topics in Obstetrics & Gynecology · doi:10.1097/01.pgo.0001028016.32068.b4 · Cited by 1
Edmonds, D. K. (2018) · Wiley eBooks · doi:10.1002/9781119211457.ch41 · Cited by 2
The evaluation and management of recurrent pregnancy loss
Bedaiwy, M. A., Elbasueny, B., Iews, M., Rowe, T., & Jiang, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85687-4.00017-8 · Cited by 1
Domali, E. (2017) · MOJ Women s Health · doi:10.15406/mojwh.2017.05.00122 · Cited by 1
Rivera, L. M. S., Molano, W. B., Junca-Ramírez, A., Fernández-Aldana, A. R., Fernández-Ávila, D. G., Jaimes, D. A., Jauregui, E. A., Segura-Charry, J. S., Romero‐Sánchez, C., & Felipe-Díaz, O. J. (2021) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2021.07.005 · Cited by 2
Recurrent Pregnancy Loss: immunological risk factors and immunomodulatory treatments
Nørgaard-Pedersen, C. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau620097234 · Cited by 2
The role of progesterone in the prevention of the “great obstetrical syndromes”: current evidence
Renzo, G. C. D., Tosto, V., Tsibizova, V. I., Bianchi, P., & Benagiano, G. (2025) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2025.2451664 · Cited by 1
Zarei, L., Behroozi-Lak, T., Hajshafiha, M., Azizzadeh, R., Talebi, A., Abdollah, S., & Hajebrahimi, A. (2018) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2018/947
“It also suppresses uterine contractions.(9,10) The impact of progesterone rise on IVF outcomes has been the subject of many studies.”
BackgroundProgesterone as therapy or prophylaxis in pregnancy
Sundin, A. S. (2018)
Evaluation and Management of Recurrent Miscarriage
Bhandari, H. M., Tewary, S., & Choudhary, M. K. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316488294.025
Comparison of Various Progesterone Drugs in Reducing Miscarriages
Zubair, H., Riaz, L., Zahra, F., Malik, S. S., & Javed, R. (2021) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs21155971
Rivera, L. M. S., Molano, W. B., Junca-Ramírez, A., Fernández-Aldana, A. R., Fernández-Ávila, D. G., Jaimes, D. A., Jauregui, E. A., Segura-Charry, J. S., Romero‐Sánchez, C., & Felipe-Díaz, O. J. (2021) · Reumatología Clínica · doi:10.1016/j.reuma.2021.09.002
Optimal Management of the First Trimester in Women over 40
Cartwright, B., & Naik, A. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009025270.011
Evaluación diagnóstica y terapéutica de los abortos de repetición
García‐Franco, A. L., Prats, A. G., Corrochano, E. C., & Iglesias, A. P. (2023) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2022.11.003
Progestagens in the prevention of spontaneous mission
Дикке, Г. Б., & Габитова, Н. А. (2023) · Russian Journal of Human Reproduction · doi:10.17116/repro20232903154
Use of progestagens to preserve pregnancy: modern approaches
Zhuk, S. I., & Us, I. (2023) · Reproductive Endocrinology · doi:10.18370/2309-4117.2023.69.36-40
Schenone, C. V., & Ros, S. T. (2023) · Wiley eBooks · doi:10.1002/9781119636540.ch32
Ott, J., Holzer, I., & Goebl, C. S. (2024) · ISGE series · doi:10.1007/978-3-031-55300-4_7
Investigation and Management of Recurrent Pregnancy Loss: A Comprehensive Review of Guidelines
Giouleka, S., Tsakiridis, I. G., Arsenaki, E., Kalogiannidis, I. A., Mamopoulos, A. M., Papanikolaou, E. G. E., Athanasiadis, A. P., & Dagklis, T. (2024) · Topics in Obstetrics & Gynecology · doi:10.1097/01.pgo.0001026740.91850.b7
Black, N., Quenby, S. M., & Odendaal, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-085929
Self-citationSukhikh, G. T., Serov, V. N., Andreeva, M. D., Артымук, Н. В., Bazina, M. I., Baranov, I. I., Башмакова, Н. В., Bezhenar, V. F., Belotserkovtseva, L. D., Geppe, N. A., et al. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-460 · Cited by 1
Supporting Maternal Autonomy in Medical Abortion Pathways
Turner, J., & Chaku, J. D. (2024) · Integrated science · doi:10.1007/978-3-031-64292-0_18
Progesterone therapy in the prevention of pregnancy loss
Altaiam, A., & Almomani, J. R. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253284
Metadata
- Authors
- Coomarasamy, A., Williams, H., Truchanowicz, E., Seed, P. T., Small, R., Quenby, S., Gupta, P., Dawood, F., Koot, Y. E., Atik, R. B., Bloemenkamp, K. W., Brady, R., Briley, A., Cavallaro, R., Cheong, Y. C., Chu, J., Eapen, A., Essex, H., Ewies, A., Hoek, A., Kaaijk, E. M., Koks, C. A., Li, T.-C., MacLean, M., Mol, B. W., Moore, J., Parrott, S., Ross, J. A., Sharpe, L., Stewart, J., Trépel, D., Vaithilingam, N., Farquharson, R. G., Kilby, M. D., Khalaf, Y., Goddijn, M., Regan, L., & Rai, R.
- Affiliations
- University of Birmingham (GB)
- St Thomas' Hospital (GB)
- Heart of England NHS Foundation Trust (GB)
- University of Warwick (GB)
- Liverpool Women's Hospital (GB)
- University Medical Center Utrecht (NL)
- The Miscarriage Association, Wakefield, UK
- Leiden University Medical Center (NL)
- St Mary's Hospital (GB)
- Princess Anne Hospital (GB)
- University of York (GB)
- Sandwell & West Birmingham Hospitals NHS Trust (GB)
- University Medical Center Groningen (NL)
- OLVG (NL)
- Máxima Medisch Centrum (NL)
- Royal Hallamshire Hospital (GB)
- University Hospital Crosshouse (GB)
- The University of Adelaide (AU)
- Nottingham University Hospitals NHS Trust (GB)
- King's College Hospital NHS Foundation Trust (GB)
- Royal Victoria Infirmary (GB)
- Queen Alexandra Hospital (GB)
- Guy's Hospital (GB)
- Amsterdam UMC Location University of Amsterdam (NL)
- Corresponding author
- Coomarasamy, Arri
- ORCID
- Coomarasamy, Arri
- Williams, Helen
- Seed, Paul T
- Small, Rachel
- Quenby, Siobhan
- Gupta, Pratima
- Bloemenkamp, Kitty WM
- Briley, Annette
- Cheong, Ying C
- Chu, Justin
- Eapen, Abey
- Essex, Holly
- Ewies, Ayman
- Hoek, Annemieke
- Koks, Carolien A
- Li, Tin-Chiu
- MacLean, Marjory
- Mol, Ben W
- Parrott, Steve
- Ross, Jackie A
- Stewart, Jane
- Trépel, Dominic
- Kilby, Mark David
- Khalaf, Yacoub
- Goddijn, Mariëtte
- Venue
- Health Technology Assessment
- Published
- 2016-05
- Volume
- 20
- Issue
- 41
- Pages
- 1-92
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- PMC
- PMC4904188
- OpenAlex
- W2403936163
- Cited by
- 109
- References
- 63
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 15 · 2022: 9 · 2021: 15 · 2020: 8 · 2019: 13 · 2018: 7 · 2017: 13 · 2016: 1
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- ePrints Soton (University of Southampton) (submittedVersion)
- Research Portal (King's College London) (submittedVersion, cc-by-nc)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Health Technology Assessment programme (08/38/01)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- progesterone therapy, unexplained recurrent spontaneous abortion, early pregnancy loss, Utrogestan, live birth rate, clinical pregnancy, ongoing pregnancy, cost-effectiveness, economic evaluation, congenital malformations, neonatal survival, resource utilization (health care), pregnancy loss prevention, spontaneous conception, PROMISE trial
- MeSH terms
- Congenital Abnormalities, Abortion, Habitual, Administration, Intravaginal, Adolescent, Adult, Cost-Benefit Analysis, Double-Blind Method, Female, Gestational Age, United Kingdom, Humans, Infant, Infant Mortality, Netherlands, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, First, Progesterone, Quality-Adjusted Life Years, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.